Key result
Statin and aspirin use is associated with improved outcomes of FCR therapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Why the study?
Does statin and aspirin use improve survival outcome in patients with relapsed/refractory chronic lymphocytic leukemia receiving FCR therapy?
Does statin and aspirin use improve survival outcome in patients with relapsed/refractory chronic lymphocytic leukemia receiving FCR therapy?
Answers are grounded in this paper and cite their sources.
Statin and aspirin use may be associated with improved survival in relapsed/refractory CLL patients undergoing FCR therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2014) studied this question. Statin and aspirin use is associated with improved outcomes of FCR therapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Synapse has enriched 10 related papers. Consider them for comparative context: